Adage Capital Partners’s TScan Therapeutics TCRX Stock Holding History

Adage Capital Partners’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,500,000	Closed	-$4.83M	–	946
2025 Q1	$4.83M	Hold	3,500,000	–	–	0.01%	703
2024 Q4	$10.6M	Sell	3,500,000 -900,000	-20%	-$4.08M	0.02%	588
2024 Q3	$21.9M	Hold	4,400,000	–	–	0.04%	428
2024 Q2	$25.7M	Buy	4,400,000 +500,000	+13%	+$3.94M	0.05%	370
2024 Q1	$31M	Hold	3,900,000	–	–	0.06%	345
2023 Q4	$22.7M	Sell	3,900,000 -100,000	-3%	-$458K	0.05%	393
2023 Q3	$10.2M	Hold	4,000,000	–	–	0.02%	556
2023 Q2	$10M	Buy	4,000,000 +3,450,000	+627%	+$9.25M	0.02%	572
2023 Q1	$1.16M	Hold	550,000	–	–	﹤0.01%	791
2022 Q4	$853K	Hold	550,000	–	–	﹤0.01%	845
2022 Q3	$1.68M	Hold	550,000	–	–	﹤0.01%	865
2022 Q2	$1.73M	Hold	550,000	–	–	﹤0.01%	889
2022 Q1	$1.54M	Hold	550,000	–	–	﹤0.01%	915
2021 Q4	$2.48M	Buy	550,000 +53,417	+11%	+$386K	﹤0.01%	861
2021 Q3	$4.14M	Buy	+496,583	New	+$4.61M	0.01%	850

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Adage Capital Partners's TCRX Position: Q2 2025 in Review

Adage Capital Partners sold out of TScan Therapeutics (TCRX) in Q2 2025, closing a stake of 3,500,000 shares — an estimated $4.83M sold.

Adage Capital Partners first reported a position in TCRX in Q3 2021 and held it in 15 quarters. The position peaked at $31M in Q1 2024. 81 funds tracked by Wall St. Rank hold TCRX as of Q2 2025.

Adage Capital Partners reported no remaining TScan Therapeutics position as of Q2 2025 after selling out during the quarter.
Adage Capital Partners sold 3,500,000 TScan Therapeutics shares in Q2 2025, an estimated $4.83M.
Adage Capital Partners first reported a position in TScan Therapeutics in Q3 2021 and held it in 15 quarters.
Adage Capital Partners's TScan Therapeutics position peaked at $31M in Q1 2024.
81 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2025.

Based on Adage Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.